San Diego Biotech Has the Labs, the Capital, and the Pipeline. It Cannot Find the People to Run Them.
San Diego delivered 1.2 million square feet of new laboratory space in 2024, with another 2.8 million in the pipeline through 2026. Venture capital kept flowing: $2.8 billion across 94 deals last year, holding the region's position as the third-largest U.S. biotech hub. And yet a Director of Cell Therapy Manufacturing role in the Torrey Pines corridor still takes seven to nine months to fill. The physical infrastructure and the financial capital are arriving. The human capital is not keeping pace.
This is the core tension defining San Diego's life sciences sector as of 2026. The market looks healthy by every conventional measure: employment at 58,000 and growing at 4.2% annually, real estate development accelerating, and a wave of late-stage IPO candidates preparing for public markets. But the roles that matter most to the next phase of this market's growth sit in cell therapy manufacturing, AI-enabled drug discovery, and FDA regulatory strategy. These are precisely the roles where candidate pools are thinnest, search durations are longest, and the gap between what employers need and what the local talent market can supply is widening rather than closing.
What follows is a ground-level analysis of why San Diego's biotech hiring challenge is more severe than headline figures suggest, where the specific pressure points sit, and what organisations operating in this market need to understand before they commit to their next critical search.
The Golden Triangle Is Growing. Its Talent Supply Is Not.
The 12-square-mile corridor stretching from Torrey Pines Mesa through Sorrento Valley to University City concentrates roughly 600 life sciences establishments. Scripps Research, the Salk Institute, Sanford Burnham Prebys, and Illumina's global headquarters all sit within this geography. UC San Diego contributes $1.4 billion in annual R&D expenditure and ranks among the top five U.S. public universities for biotech patent generation. The cluster's density is matched only by Boston's Kendall Square.
Employment across the San Diego-Carlsbad metropolitan area reached approximately 58,000 life sciences workers by late 2024, representing 3.9% of regional employment against a national average of 0.9%. The sector generated $38.4 billion in regional economic output in 2023. These are not small numbers. They describe a market with genuine critical mass.
But aggregate figures conceal a bifurcation that defines everything about hiring in this region. Biotech unemployment in San Diego sits at 2.1%, below the sector's national average of 2.8%. For research associates and clinical research coordinators, active candidate ratios remain healthy at 60 to 65%, and roles fill in 45 to 60 days. The system works at this level.
It breaks down entirely at the specialist and executive tier. Chief Medical Officers and VP-level Clinical Development leaders show passive candidate ratios of approximately 85%. For PhD-level AI and machine learning drug discovery leads, that figure reaches 90%. Cell therapy manufacturing directors sit at 75% passive, with average tenure at current employers exceeding five years. These are not people browsing job boards. They are not considering a move. Reaching them requires a fundamentally different method, and the firms that have not adapted to this reality are the ones running searches that stretch past six months with nothing to show for it.
The investment that has transformed San Diego's physical infrastructure has not produced a proportional increase in the people qualified to work inside it. Capital moved faster than human capital could follow. That single dynamic explains more about this market's hiring difficulty than any other factor.
Where the Searches Stall: Three Roles That Define the Shortage
Cell Therapy Manufacturing Leadership
Roche's $1.1 billion acquisition of Poseida Therapeutics in December 2024 put a spotlight on San Diego's cell therapy ambitions. It also put a spotlight on how thin the talent bench is. Following the acquisition, Roche reportedly implemented retention packages for San Diego-based Director and VP-level Cell Manufacturing talent averaging $75,000 to $125,000 in additional annual equity grants above standard compensation bands. The purpose was not attraction. It was preventing attrition during the 18-month integration period.
This pattern is consistent with broader market data. Cell therapy process development roles in the Torrey Pines corridor typically remain unfilled for seven to nine months, with 68% of positions requiring sourcing from outside the San Diego market entirely. The pool of professionals with GMP facility design experience, closed-system bioreactor operation capability, and CMC strategy knowledge for autologous and allogeneic products is genuinely small. It is not growing at the rate the sector demands.
The cell and gene therapy subsector is projected to drive 60% of new specialised hiring in San Diego through 2026. This concentration of demand against a shallow talent pool means that every new entrant hiring in this space competes directly with Roche, Fate Therapeutics, and Thermo Fisher for the same finite group of experienced leaders. The economics of that competition are already visible in the retention premiums being deployed.
AI and Machine Learning Drug Discovery
Series B and C financings for AI/ML-enabled drug discovery platforms surged 34% year-over-year in San Diego in 2024, even as overall venture deployment contracted 22% from 2021 peaks. The capital is rotating, not retreating. But the rotation is creating demand for a profile that barely existed five years ago: scientists who combine deep genomics expertise with computational fluency at a level sufficient for drug target identification and generative chemistry applications.
The search durations tell the story. Mid-stage San Diego biotechs report Director of Data Science roles in drug discovery remaining open for 180 to 220 days, with 40% of searches failing to yield viable local candidates. The resolution in most cases involves relocation from the Bay Area or Boston, which introduces its own friction. The Bay Area compensates 18 to 25% higher for equivalent roles. Boston sits 15 to 20% above San Diego. Convincing a computational biologist to move south requires a compelling narrative beyond salary, because the salary will almost certainly be lower.
The 90% passive candidate ratio for PhD-level AI drug discovery leads means that conventional job advertising reaches almost none of them. These professionals average 4.2 years of tenure at their current employers. They are not dissatisfied. They are not looking. They must be identified, approached directly, and given a reason to consider a conversation.
Regulatory Strategy Executives with FDA CBER Experience
San Diego's third acute shortage sits at the intersection of science and regulation. The FDA's Center for Biologics Evaluation and Research maintains limited presence in San Diego, with primary hubs in Maryland and Boston. This geographic distance creates real operational friction for cell therapy companies requiring frequent pre-IND meetings. It also means that regulatory executives with direct CBER interaction experience tend to cluster in the Mid-Atlantic and New England, not on the West Coast.
Market patterns show that recruiting VP-level Regulatory Affairs talent with CBER approval experience into San Diego requires substantial financial incentives. Cross-country relocations for these roles typically involve signing bonuses in the range of $50,000 and base salary premiums of 30 to 35% above the candidate's previous compensation. These are not discretionary costs. They reflect the structural scarcity of a skillset that cannot be developed locally at the pace the market requires.
The convergence of these three shortages is what makes San Diego's situation genuinely distinct from a generic hiring challenge. Cell therapy, AI drug discovery, and biologics regulatory strategy are not independent labour markets. They overlap. A cell therapy company needs manufacturing leaders, computational scientists to design the therapies, and regulatory strategists to move them through the FDA. A shortage in one function constrains progress across all three.
The Compensation Equation: Cheaper Than the Bay Area, Expensive Enough to Struggle
San Diego occupies an unusual position in the national life sciences compensation hierarchy. It commands a 12 to 15% discount to San Francisco Bay Area pay for equivalent roles, but a 5 to 8% premium over Research Triangle Park and Seattle. This middle position creates a specific challenge that neither the cheapest nor the most expensive markets face.
At the senior specialist and director level, the numbers are substantial. A Principal Scientist in Genomics or NGS earns $175,000 to $225,000 in base salary, with 15 to 20% target bonus and $50,000 to $80,000 in annual equity. A Director of CMC in cell therapy commands $220,000 to $275,000 base, 20 to 25% bonus, and $100,000 to $150,000 in equity. Directors of Computational Biology sit at $210,000 to $260,000 base with equity packages reaching $200,000.
At the executive tier, total direct compensation escalates sharply. Vice Presidents of Research or Early Development earn $385,000 to $525,000 base with long-term incentive values of $400,000 to $800,000. Chief Medical Officers at public companies reach $450,000 to $650,000 base, with total direct compensation spanning $1.2 to $2.5 million. Chief Scientific Officers at clinical-stage companies command $425,000 to $600,000 base with equity grants of $1.0 to $1.8 million.
These figures are not low. But they exist in the context of a median home price of $985,000 in San Diego, compared to $1.35 million in San Francisco and $1.1 million in Boston. The cost-of-living discount relative to the Bay Area is real but narrower than the compensation discount. According to the S&P CoreLogic Case-Shiller Index, San Diego housing costs have continued to rise faster than the national average, with a rent burden of 34.2% for life sciences professionals earning $120,000 to $150,000.
A UC San Diego Extension survey from 2024 found that 28% of San Diego biotech workers were considering relocation to lower-cost markets within 24 months, citing Austin, Research Triangle Park, and Salt Lake City as destinations. Seattle compounds the pressure differently: its 8 to 10% compensation premium for computational biology roles arrives with no state income tax, making the net financial calculation heavily favour Washington.
For hiring leaders, the implication is concrete. San Diego cannot compete with the Bay Area on raw compensation. It can offer lifestyle, climate, and a lower total cost of living, but only if the compensation package is structured to make the comparison visible. A candidate weighing a Bay Area offer against a San Diego one needs to see the housing differential, the commute differential, and the equity upside laid out explicitly. Firms that present a base salary number without this context lose candidates they should be winning.
The Lab Space Paradox: Physical Supply Without Human Demand
The real estate data appears to contradict the hiring data. Overall San Diego life sciences vacancy reached 13.5% in Q3 2024, up from 6.2% in 2021. Speculative lab developments sit at 18% vacancy. New supply keeps arriving: 2.8 million square feet in the pipeline for 2025 and 2026, including the 485,000-square-foot Science Center at Torrey Pines and the 320,000-square-foot Boardwalk in UTC.
But the contradiction dissolves on closer inspection. The vacancy figures describe two completely different markets.
Class A laboratory space in the Torrey Pines submarket sits at 8.5% vacancy, with effective rents of $78 to $85 per square foot NNN. Build-to-suit facilities for established entities like Illumina and Thermo Fisher maintain sub-5% vacancy. The tightness at the top end is real and persistent.
The elevated headline vacancy comes almost entirely from speculative developments aimed at startups and early-stage companies. An average Series A biotech in San Diego allocates 22% of raised capital to facility costs, compared to 15% in Research Triangle Park. This cost pressure pushes pre-revenue companies to outsource R&D or delay local expansion, leaving spec lab inventory sitting empty even as anchor tenants compete fiercely for premium space.
The result is a market where the physical capacity to grow exists but the human capacity does not. The lab buildings being delivered in 2026 will not create talent. They will absorb Series C and later companies with the capital to hire. But those companies will draw from the same constrained talent pool that is already producing seven-month search durations for manufacturing directors and 180-day vacancies for computational biologists. New square footage without new people is infrastructure waiting for occupants who may not arrive in time.
According to CBRE's Life Sciences research, Class A lab rents in San Diego are projected to remain 12 to 15% above 2019 levels in real terms through 2026, maintaining cost barriers that keep early-stage companies out of the premium space where talent already concentrates. The physical bifurcation mirrors and reinforces the talent bifurcation.
What the Capital Rotation Means for Who Gets Hired
San Diego's venture capital story is not a contraction story. It is a rotation story, and the rotation carries direct consequences for which roles are in demand and which face potential oversupply.
Total life sciences venture investment declined 22% from 2021 peaks to $2.8 billion in 2024. Consistent with national corrections in biotech valuations, this headline number suggests a market cooling off. But within that aggregate, AI/ML-enabled drug discovery platforms captured 34% year-over-year growth in local investment specifically. The money is not leaving San Diego. It is moving from traditional discovery modalities toward computational and technology-driven approaches.
This sectoral rotation has implications that headline employment figures do not capture. San Diego's 4.2% annual employment growth projection includes both traditional medicinal chemistry hiring and the new computational biology demand. But the growth is not distributed evenly. Computational roles face extreme scarcity. Traditional antibody development and small-molecule chemistry roles, while still necessary, face a softer market as capital shifts away from conventional platforms.
The risk for hiring leaders is misreading the aggregate data. A 4.2% growth rate and 2.1% unemployment rate suggest a tight but manageable market. The reality is two overlapping labour markets with opposite characteristics. One is competitive but navigable. The other involves six-month searches, relocation packages, and retention bonuses that exceed the base salary of junior staff.
Roche's acquisition of Poseida and Regeneron's expansion into San Diego signal that large pharma is betting on the region's cell therapy and advanced manufacturing capacity. Novo Nordisk's ongoing expansion of DTx Pharma reinforces the pattern. But each acquisition and expansion announcement adds demand to a talent pool that was already insufficient. An anticipated Federal Reserve rate stabilisation and the potential unlocking of IPO windows for San Diego's 45 venture-backed biotechs with late-stage assets would add further pressure still, as newly public companies compete for the same scarce leadership.
Federal Funding Risk and the Innovation Pipeline
The talent challenges in San Diego's biotech market exist within a broader context of policy uncertainty that could either amplify or moderate the pressure.
San Diego's non-profit research institutes receive approximately $680 million in annual NIH funding. UC San Diego and Scripps Research derive 35 to 40% of their operating budgets from federal sources. Potential 10 to 15% reductions in NIH appropriations under ongoing federal budget negotiations represent a material risk to the pipeline of early-stage research that feeds commercial spinout activity. FASEB's funding analysis has tracked the growing gap between NIH appropriations and the cost of maintaining research capacity at the nation's leading institutions.
Scripps Research alone has spun out 47 active biotech companies since 2019, and UC San Diego's School of Medicine produces over 150 life sciences PhDs annually. A sustained reduction in federal research funding would not eliminate this pipeline, but it would slow it. Fewer spinouts means fewer companies competing for scarce talent in the short term, but also a thinner foundation for the market's long-term capacity to generate both companies and the scientists who staff them.
The Inflation Reduction Act's Medicare price negotiation provisions add a second layer of uncertainty. Pfizer and Bristol Myers Squibb have restructured early-stage pipeline priorities in response, with local biotechs reporting 12% longer decision timelines for collaboration agreements with large pharma partners. These delays do not reduce demand for talent directly. They extend the period during which small companies must maintain expensive leadership teams without the partnership revenue that often supports them.
Neither of these risks is catastrophic in isolation. But together they create an environment where the organisations that move fastest on hiring have a compounding advantage. Delay is not neutral in this market. Every month a critical role remains open is a month in which a competitor is building the team, securing the partnership, or advancing the programme that the open position was meant to support.
What This Market Requires From a Hiring Strategy
San Diego's biotech talent market does not reward patience. It rewards precision and speed.
The passive candidate ratios alone make the case. When 85 to 90% of the viable candidates for your most critical roles are not looking, not applying, and not visible on any job board or LinkedIn search, traditional recruitment methods reach a fraction of the people you need. A posted VP of Research vacancy in San Diego does not attract the Chief Scientific Officer at a competing clinical-stage company who might be the perfect fit. That person must be identified through systematic market intelligence, approached with a specific and credible proposition, and managed through a process that respects both their current obligations and the timeline your organisation faces.
The compensation dynamics add urgency. Because San Diego sits in the middle of the national pay hierarchy for life sciences, every search involves an implicit comparison to what the Bay Area and Boston would offer. A search process that takes six months gives a passive candidate ample time to receive and entertain competing approaches from markets that pay more. Speed is not a convenience. It is a competitive requirement.
KiTalent's approach to executive hiring in the life sciences and healthcare sector is designed for exactly this type of market. Using AI-powered talent mapping to identify passive candidates across competing geographies, combined with direct headhunting that reaches the 80% of leaders who never appear on a job board, KiTalent delivers interview-ready candidates within 7 to 10 days. The pay-per-interview model means organisations invest only when they are meeting qualified people, not when a search begins.
With a 96% one-year retention rate across 1,450 executive placements, the approach reflects a core principle: in markets where the talent pool is this thin and this passive, the quality of the initial identification and approach determines everything. A wrong shortlist is not just a delay. It is a signal to the market that your organisation could not attract the right person.
For organisations competing for cell therapy manufacturing leadership, AI drug discovery scientists, or regulatory strategy executives in San Diego's biotech corridor, where the cost of a failed search compounds monthly and the best candidates will never see your job posting, start a conversation with our executive search team about how we approach this market differently.
Frequently Asked Questions
What is the average time to fill a senior biotech role in San Diego?
It depends sharply on the function. Research associates and clinical research coordinators fill in 45 to 60 days. But specialised roles tell a different story. Cell therapy manufacturing director positions in the Torrey Pines corridor typically take seven to nine months. Director of Data Science roles in drug discovery average 180 to 220 days. The difference reflects passive candidate ratios: at the specialist level, 75 to 90% of qualified professionals are employed, not looking, and unreachable through job postings. Proactive search through direct headhunting is the only reliable method for these roles.
How does San Diego biotech compensation compare to Boston and San Francisco?
San Diego commands a 12 to 15% discount to Bay Area compensation for equivalent roles and sits 15 to 20% below Boston for cell therapy and regulatory executives. However, San Diego's median home price of $985,000 compares favourably to San Francisco's $1.35 million and Boston's $1.1 million. The net calculation varies by seniority. At the VP level and above, where total direct compensation reaches $1 to $2.5 million, the lifestyle and cost-of-living differential can offset the nominal pay gap. Below that threshold, it increasingly cannot.
What biotech subsectors are driving hiring growth in San Diego in 2026?
Cell and gene therapy is the dominant driver, projected to account for 60% of new specialised hiring through 2026. AI and machine learning drug discovery is the fastest-growing subsector by investment, with Series B and C funding up 34% year-over-year in 2024 despite a broader venture correction. Neuroscience therapeutics remain a stable employer through anchor companies like Neurocrine Biosciences and Acadia Pharmaceuticals, while genomics hiring continues around Illumina's ecosystem.
Why is it so difficult to hire regulatory affairs executives in San Diego?
The core issue is geographic. The FDA's Center for Biologics Evaluation and Research operates primarily from Maryland and Boston. Regulatory executives with direct CBER interaction experience cluster near those hubs. Recruiting them to San Diego requires cross-country relocation, typically supported by signing bonuses and base salary premiums of 30 to 35%. The scarcity is systemic rather than cyclical: San Diego's cell therapy pipeline is growing faster than the local regulatory talent pool, creating a persistent gap that requires international and cross-market executive search to address.
What role does AI play in San Diego's biotech hiring challenges?
AI creates both demand and competition. San Diego's AI/ML drug discovery platforms attracted 34% more venture funding year-over-year in 2024, generating intense demand for computational biologists and data scientists with genomics expertise. Simultaneously, technology companies in Seattle and the Bay Area compete for the same profiles, offering higher compensation and, in Seattle's case, no state income tax. The result is a 90% passive candidate ratio for PhD-level AI drug discovery leads and search durations exceeding 180 days for director-level roles.
How can companies improve biotech executive hiring outcomes in San Diego?
Three adjustments make the largest difference. First, accept that the viable candidate pool is overwhelmingly passive and invest in direct identification methods rather than job advertising. Second, structure compensation packages that make the Bay Area comparison explicit, showing candidates the housing differential and total cost of living rather than relying on base salary alone. Third, compress your hiring timeline. In a market where the strongest candidates receive multiple approaches, a six-month search process consistently loses to a firm that can move from identification to offer in weeks rather than months.
